🇺🇸 Carboplatin AUC2 in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 7
Most-reported reactions
- Alanine Aminotransferase Increased — 1 report (14.29%)
- Anaemia — 1 report (14.29%)
- Hypokalaemia — 1 report (14.29%)
- Kidney Infection — 1 report (14.29%)
- Packed Red Blood Cell Transfusion — 1 report (14.29%)
- Sepsis — 1 report (14.29%)
- Urinary Tract Infection — 1 report (14.29%)
Other Oncology approved in United States
Frequently asked questions
Is Carboplatin AUC2 approved in United States?
Carboplatin AUC2 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Carboplatin AUC2 in United States?
Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.